Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®
03 juin 2020 01h00 HE
|
Lupin Ltd
Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic...
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
19 oct. 2018 07h44 HE
|
Lupin Neurosciences Ltd
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, October 19, 2018: Lupin Neurosciences, a...